Peregrine Pharmaceuticals, Inc. (PPHM) to Present Bavituximab Antiviral Data at 2010 Chemical and Biological Defense Science and Technology Conference  
10/20/2010 9:19:22 AM

TUSTIN, CA--(Marketwire - October 20, 2010) -

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from a preclinical study of bavituximab have been accepted for presentation at the 2010 Chemical and Biological Defense Science and Technology Conference, to be held November 15-19, 2010 in Orlando, Florida.

"Targeting of Anionic Phospholipids Exposed on Infected Cells and Virions: Potential broad-Spectrum Antiviral Therapy" (abstract T02-003) will be presented in a poster session on Tuesday, November 16, 2010 from 6:00 pm to 8:00 pm EST.

For additional information about the conference, please visit

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (, which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at

Amy Figueroa
Peregrine Pharmaceuticals
(800) 987-8256